Abstract
The oral cavity of human immunodeficiency virus type I (HIV-1) infected individuals is subjected to a series of opportunistic infections which are usually considered as a prognostic marker for the severity of infection as well as an indicator of immunodeficiency. The highly active antiretroviral therapy (HAART) has significantly lessened the severity of HIV-associated oral infections although this therapeutic regimen is considered to be responsible for some of the oral lesions such as oral warts and salivary gland disorders. In addition, the beneficial effects of HAART on HIV associated oral lesions are stratified with age, with the adult population showing improvements whereas the oral lesions among children remain unchanged with this therapy. The presence of HIV-1 in the saliva, and infectivity of oral epithelial cells suggest that the oral cavity is a site of HIV pathogenesis and potential reservoir for the disease in the setting of virally suppressive HAART. Overall HIV associated oral lesions ar e usually due to fungal, bacterial, and viral infections as well as some of unknown etiology. This review describes the current status of HIV associated oral lesions by comparing historically available pre- HAART data. Future directions envisioned by the National Institutes of Health as well as novel avenues to be explored are also presented.
Keywords: Non-nucleoside reverse transcriptase inhibitors, Nucleoside reverse transcriptase inhibitors, AIDS, Salivery glands, Antimicrobial, Oral Cavity, Human Papillomavirus
Current HIV Research
Title: Effects of Highly Active Antiretroviral Therapy on HIV-1-Associated Oral Complications
Volume: 5 Issue: 3
Author(s): Zahida Parveen, Edward Acheampong, Roger J. Pomerantz, Jeffrey M. Jacobson, Brian Wigdahl and Muhammad Mukhtar
Affiliation:
Keywords: Non-nucleoside reverse transcriptase inhibitors, Nucleoside reverse transcriptase inhibitors, AIDS, Salivery glands, Antimicrobial, Oral Cavity, Human Papillomavirus
Abstract: The oral cavity of human immunodeficiency virus type I (HIV-1) infected individuals is subjected to a series of opportunistic infections which are usually considered as a prognostic marker for the severity of infection as well as an indicator of immunodeficiency. The highly active antiretroviral therapy (HAART) has significantly lessened the severity of HIV-associated oral infections although this therapeutic regimen is considered to be responsible for some of the oral lesions such as oral warts and salivary gland disorders. In addition, the beneficial effects of HAART on HIV associated oral lesions are stratified with age, with the adult population showing improvements whereas the oral lesions among children remain unchanged with this therapy. The presence of HIV-1 in the saliva, and infectivity of oral epithelial cells suggest that the oral cavity is a site of HIV pathogenesis and potential reservoir for the disease in the setting of virally suppressive HAART. Overall HIV associated oral lesions ar e usually due to fungal, bacterial, and viral infections as well as some of unknown etiology. This review describes the current status of HIV associated oral lesions by comparing historically available pre- HAART data. Future directions envisioned by the National Institutes of Health as well as novel avenues to be explored are also presented.
Export Options
About this article
Cite this article as:
Parveen Zahida, Acheampong Edward, Pomerantz J. Roger, Jacobson M. Jeffrey, Wigdahl Brian and Mukhtar Muhammad, Effects of Highly Active Antiretroviral Therapy on HIV-1-Associated Oral Complications, Current HIV Research 2007; 5 (3) . https://dx.doi.org/10.2174/157016207780636533
DOI https://dx.doi.org/10.2174/157016207780636533 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in people living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets Vpr-Induced DNA Double-Strand Breaks: Molecular Mechanism and Biological Relevance
Current HIV Research Trabectedin in Cancers: Mechanisms and Clinical Applications
Current Pharmaceutical Design Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches
Current Pharmaceutical Design Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Inhibition of Protein Tyrosine Phosphatase 1B: A Promising Strategy for the Treatment of Obesity and Type 2 Diabetes Mellitus
Current Medicinal Chemistry Inverse Regulation of MMP-9 and MMP-2 in Long-Term Follow-up After Acute Coronary Syndrome: Lack of Correlation with Platelet and Endothelial Cell Activation Markers
Vascular Disease Prevention (Discontinued) Promotion of Optimized Protein Therapy by Bioconjugation as a Polymeric DDS
Anti-Cancer Agents in Medicinal Chemistry Cellular and Physiological Effects of Ganoderma lucidum (Reishi)
Mini-Reviews in Medicinal Chemistry Clinical Applications of Cardiovascular Magnetic Resonance
Current Pharmaceutical Design Dexrazoxane for the Prevention of Cardiac Toxicity and Treatment of Extravasation Injury from the Anthracycline Antibiotics
Current Pharmaceutical Biotechnology The Voyage of Natural Chalcone: Isoliquiritigenin
Current Bioactive Compounds Update of Targeted Therapy-Induced Hypertension: Basics for Non-Oncology Providers
Current Hypertension Reviews Multiple Roles of Annexin A2 in Post-Transcriptional Regulation of Gene Expressio
Current Protein & Peptide Science Emerging Methods for Ensemble-Based Virtual Screening
Current Topics in Medicinal Chemistry Neutrophil Activation Induced by Plant Lectins: Modulation of Inflammatory Processes
Inflammation & Allergy - Drug Targets (Discontinued) FOXO1: A Potential Target for Human Diseases
Current Drug Targets Polycistronic Viral Vectors
Current Gene Therapy Interferon-Beta Therapy Monitoring in Multiple Sclerosis Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Between Bench and Bed Side: PI3K Inhibitors
Current Molecular Pharmacology